A. Badiee, M. R. Jaafari, and A. Khamesipour, Leishmania major: Immune response in BALB/c mice immunized with stress-inducible protein 1 encapsulated in liposomes, Experimental Parasitology, vol.115, issue.2, pp.127-134, 2007.
DOI : 10.1016/j.exppara.2006.07.002

C. Bordier, The promastigote surface protease of leishmania, Parasitology Today, vol.3, issue.5, pp.151-153, 1987.
DOI : 10.1016/0169-4758(87)90199-2

L. L. Button and W. R. Mcmaster, Molecular cloning of the major surface antigen of leishmania, Journal of Experimental Medicine, vol.167, issue.2, pp.724-729, 1988.
DOI : 10.1084/jem.167.2.724

R. N. Coler and S. G. Reed, Second-generation vaccines against leishmaniasis. 512 Trends Parasitol, pp.244-249, 2005.

M. J. Copland, T. Rades, N. M. Davies, and M. A. Baird, Lipid based particulate formulations for the delivery of antigen, Immunology and Cell Biology, vol.45, issue.2, pp.97-105, 2005.
DOI : 10.1016/S0169-409X(98)00013-1

S. L. Croft and G. H. Coombs, Leishmaniasis??? current chemotherapy and recent advances in the search for novel drugs, Trends in Parasitology, vol.19, issue.11, pp.502-508, 2003.
DOI : 10.1016/j.pt.2003.09.008

C. Foged, B. Brodin, S. Frokjaer, and A. Sundblad, Particle size and surface charge 518 affect particle uptake by human dendritic cells in an in vitro model, Int. J, vol.519, issue.298, pp.315-322, 2005.

A. Ghadiri, V. Rogozhkina, R. Mashko, R. W. Mcmaster, and F. Mahboudi, High 521 level expression of Leishmania major gp63 gene in different strains of E. coli 522 under the control of lambda p1 Promoter, IX International Congress of 523 Parasitology, pp.875-881, 1998.

G. Gregoriadis, The Immunological Adjuvant and Vaccine Carrier Properties of Liposomes, Journal of Drug Targeting, vol.66, issue.5, pp.351-356, 1994.
DOI : 10.1042/bst0170695

R. K. Grencis, Th2-mediated host protective immunity to intestinal nematode infections, Philosophical Transactions of the Royal Society B: Biological Sciences, vol.352, issue.1359, pp.1377-1384, 1997.
DOI : 10.1098/rstb.1997.0123
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1692029

M. Henriksen-lacey, A. Devitt, and Y. Perrie, The vesicle size of DDA:TDB 529, 2011.

F. Barkhordari, A. Khamesipour, and W. R. Mcmaster, Immune response and 533 protection assay of recombinant major surface glycoprotein of Leishmania 534 (rgp63) reconstituted with liposomes in BALB/c mice, Vaccine, vol.24, pp.5708-5717, 2006.

L. Kedzierski, Y. Zhu, and E. Handman, Leishmania vaccines: progress and problems, Parasitology, vol.170, issue.S2, pp.87-112, 2006.
DOI : 10.1017/S0031182006001831

F. Modabber, Leishmanization: use of an old method for evaluation of 543 candidate vaccines against leishmaniasis, Vaccine, vol.23, pp.3642-3648, 2005.

L. Leserman, Liposomes as Protein Carriers in Immunology, Journal of Liposome Research, vol.9, issue.3-4, pp.175-189, 2004.
DOI : 10.1038/nrc1235

O. H. Lowry, N. J. Rosebrough, A. L. Farr, and R. J. Randall, Protein measurement 550 with the Folin phenol reagent, J. Biol. Chem, vol.193, pp.265-275, 1951.

J. Mauel, Vaccination against Leishmania infections, Curr. Drug Targets, p.559, 2002.

D. N. Mclennan, C. J. Porter, and S. A. Charman, Subcutaneous drug delivery and the role of the lymphatics, Drug Discovery Today: Technologies, vol.2, issue.1, pp.89-96, 2005.
DOI : 10.1016/j.ddtec.2005.05.006

F. Modabber, Vaccines against leishmaniasis, Annals of Tropical Medicine & Parasitology, vol.145, issue.sup1, pp.563-83, 1995.
DOI : 10.1016/0166-6851(94)90057-4

I. Sharifi, E. A. Khalil, I. D. Bernal, C. M. Antunes, and P. G. Smith, Efficacy of 570 killed whole-parasite vaccines in the prevention of leishmaniasis: a meta- 571 analysis, Vaccine, vol.27, pp.4747-4753, 2009.

D. T. Hagan, N. M. Christy, and S. S. Davis, Particulates and lymphatic drug 573 delivery, Lymphatic Transport of Drugs, pp.294-310, 1992.

D. K. Mcmaster and W. R. , Vaccination of vervet monkeys against cutaneous 577 leishmaniosis using recombinant Leishmania 'major surface glycoprotein' 578 (gp63), Vet. Parasitol, vol.60, pp.199-212, 1995.

D. Sacks and N. Noben-trauth, The immunology of susceptibility and resistance 580, 2002.

C. Taswell, Limiting dilution assays for the determination of 582 immunocompetent cell frequencies. I. Data analysis, Immunology, vol.126, pp.1614-583, 1981.

R. G. Titus, M. Marchand, T. Boon, and J. A. Louis, A limiting dilution assay for 585, 1985.

V. P. Torchilin, Recent advances with liposomes as pharmaceutical carriers, Nature Reviews Drug Discovery, vol.103, issue.2, p.588, 2005.
DOI : 10.1081/LPR-120017488

K. K. Tran and H. Shen, The role of phagosomal pH on the size-dependent 590, 2009.

M. Plebanski, Pathogen recognition and development of particulate 593 vaccines: does size matter, pp.1-9, 2006.